Skip to main content

Baker McKenzie and Cyril Amarchand Mangaldas have advised Unilever on its agreement to buy GlaxoSmithKline Horlicks nutrition business in India for $3.8 billion, with Slaughter and May and AZB & Partners representing the sellers.

According to Reuters, while many of Unilever’s recent acquisitions focussed on beauty and personal care products, buying the popular malted drink Horlicks is an opportunity for the Anglo-Dutch group to increase its scale in the country, particularly in food and drinks.

The transaction covers GSK’s health food and drinks portfolio in India, Bangladesh and 20 other predominantly Asian markets. The business has annual sales of around $625 million, Reuters added.

The Cyril Amarchand Mangaldas team was led by Mumbai-based managing partner Cyril Shroff, who was supported along with Bangalore corporate partner Nivedita Rao and Mumbai corporate partner Ramgovind Kuruppath, New Delhi IP partner Ranjan Negi, Mumbai competition partner Bharat Budholia and head of taxation Daksha Baxi.

 

To contact the editorial team, please email ALBEditor@thomsonreuters.com.

Related Articles

Deals

Khaitan, JSA, Hogan Lovells guide $515 mln Waaree IPO

by Nimitt Dixit |

Khaitan & Co has advised Waaree Energies, India's largest manufacturer and exporter of solar modules, on its $515 million initial public offering, with JSA Advocates & Solicitors and Hogan Lovells guiding the bookrunning lead managers.

Deals

CAM, Khaitan guide Adani-backed Renew Exim’s $380 mln ITD acquisition

by Nimitt Dixit |

Cyril Amarchand Mangaldas has advised Adani Group's Dubai-based firm Renew Exim DMCC on its acquisition of a 46.64 percent stake in ITD Cementation India for around $380 million from Italian-Thai Development Public Company, who was represented by Khaitan & Co.

Deals

CAM, AZB, SAM, Latham advise on landmark $1.3 bln Swiggy IPO

by Nimitt Dixit |

Cyril Amarchand Mangaldas is advising SoftBank-backed Indian food and grocery delivery giant Swiggy on its much-anticipated initial public offering worth $1.3 billion, with AZB & Partners and Latham & Watkins advising the bookrunning lead managers.